Vivos Therapeutics, Inc. VVOS
0.14
(0.01)
(6.67%)
as of 25 Sep
- Market cap
- $4.9M
- P/E
- 0.0×
Follow VVOS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 10,022.05% | (1,470.75%) | (661.15%) | (335.47%) |
+8 more TTM periods Free account |
|
| (101.46%) | (137.58%) | (104.71%) | (83.45%) | ||
ROIC |
(592.70%) | (325.33%) | (237.15%) | (124.97%) | |
Return on Tangible Assets |
203.06% | 260.51% | 213.09% | (428.56%) | |
Average Days of Receivables |
25.11 | 33.00 | 33.08 | 44.98 | |
Free Cash Flow per Share |
(1.08) | (1.35) | (1.71) | (1.40) | |
Free Cash Flow |
(19.01) | (19.71) | (17.60) | (15.37) | |
Capital Expenditures |
(1.88) | (2.24) | (2.34) | (0.97) | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(289.08%) | (204.17%) | (164.10%) | (100.38%) | |
Accounts Receivable Turnover |
13.61 | 15.74 | 17.35 | 13.38 | |
Accounts Payable Turnover |
3.38 | 4.67 | 4.97 | 4.82 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
134.98 | 97.45 | 88.80 | 100.16 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
161.22% | 169.14% | 166.98% | 144.16% | |
Share Based Compensation of Revenue |
4.25% | 5.16% | 3.79% | 3.90% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.70 | 0.72 | 0.84 | |
Depreciation/Fixed assets |
0.49 | 0.45 | 0.35 | 0.18 | |
Capex/Depreciation |
(1.05) | (1.41) | (1.79) | (0.96) | |
Revenue per Share |
1.18 | 1.34 | 1.70 | 1.58 | |
Operating CF per Share |
(0.97) | (1.19) | (1.49) | (1.31) | |
Capex per Share |
(0.11) | (0.15) | (0.23) | (0.09) | |
Capex to Sales |
0.09 | 0.11 | 0.13 | 0.06 | |
Net Profit Margin |
(121.79%) | (127.70%) | (121.37%) | (98.77%) |
Columns are period end dates